The current stock price of BJDX is 3.25 USD. In the past month the price increased by 25%. In the past year, price decreased by -77.36%.
ChartMill assigns a technical rating of 1 / 10 to BJDX. When comparing the yearly performance of all stocks, BJDX is a bad performer in the overall market: 96.77% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to BJDX. BJDX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months BJDX reported a non-GAAP Earnings per Share(EPS) of -33.6. The EPS increased by 97.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -410.48% | ||
| ROE | -543.59% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.55 | 193.136B | ||
| ISRG | INTUITIVE SURGICAL INC | 48.44 | 174.712B | ||
| SYK | STRYKER CORP | 23.88 | 136.172B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.2 | 109.878B | ||
| BDX | BECTON DICKINSON AND CO | 10.9 | 59.193B | ||
| IDXX | IDEXX LABORATORIES INC | 43.64 | 51.087B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.92 | 44.567B | ||
| RMD | RESMED INC | 21.46 | 40.282B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.77 | 36.023B | ||
| DXCM | DEXCOM INC | 27 | 27.364B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Bluejay Diagnostics Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Acton, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-11-10. Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. The company develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. The company is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
BLUEJAY DIAGNOSTICS INC
360 Massachusetts Avenue, Suite 203
Acton MASSACHUSETTS US
Employees: 5
Phone: 19786310152
Bluejay Diagnostics Inc is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Acton, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-11-10. Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. The company develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. The company is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
The current stock price of BJDX is 3.25 USD. The price increased by 4.17% in the last trading session.
BJDX does not pay a dividend.
BJDX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
BJDX stock is listed on the Nasdaq exchange.
You can find the ownership structure of BLUEJAY DIAGNOSTICS INC (BJDX) on the Ownership tab.